Intra-Cellular Therapies Stock Price and Value Analysis

Should you buy Intra-Cellular Therapies stock? (NasdaqGS:ITCI). Let's see how it does in our automated value investing analysis system.

  • This company has stable growth.
  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the ITCI Numbers

ITCI Price
(Intra-Cellular Therapies stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 25%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 4,024,841 shares shorted. With 87,379,199 shares available for purchase and an average trading volume over the past 10 trading days of 528,230, it would take at least 7.619 days for all of the short holders to cover their shorts.

Is Intra-Cellular Therapies Stock on Sale?

Based on our analysis, we believe that you should not buy Intra-Cellular Therapies right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ITCI Stock?

Does Intra-Cellular Therapies have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.